Calypte Biomedical to Begin Shipping HIV-1 Incidence Test
PLEASANTON, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it will begin shipping its HIV-1 BED Incidence EIA test (Incidence Test) this week. The first shipment is destined for South Africa, and the Company currently has initial orders for approximately 12,000 tests worldwide. Shipments to China and Brazil should commence in the coming weeks.
In April 2004, the Company announced that it had been granted a worldwide non-exclusive license by the United States Centers for Disease Control and Prevention (CDC) to commercially manufacture and sell a unique test that was developed by the CDC in order to help epidemiologists and researchers estimate the spread of HIV-1 infection. The Incidence Test employs epitopes from three subtypes of HIV-1 known as B, E, and D, the test can be used on all of the major subtypes of HIV-1 that are found around the world.
Unlike most HIV antibody tests that are designed as a screening test to determine if an individual has been exposed to HIV-1, the Incidence Test is a population research tool intended to be used on populations already known to be infected in order to determine how many of the infections occurred in the last 6 months. Such information may give policy makers and program managers valuable insights regarding the success of their prevention programs and how best to allocate resources.
The test is believed to be valuable for targeting populations with a high incidence of HIV infections for interventional studies and/or vaccine trials. It can also be used to evaluate the effectiveness of intervention efforts by showing either a negative or positive change in the incidence of infections following the intervention effort. The Calypte HIV-1 BED Incidence EIA test is for use in research to estimate the incidence of HIV-1 in a population. It is not for use as a diagnostic test.
Dr. Richard George, President and CEO of Calypte said, "We have successfully transferred the manufacturing process for the Incidence Test from the CDC to Calypte in very short order, and that is a great accomplishment for our staff. We are encouraged by the reception that we have received from HIV researchers who have expressed strong interest in this product, and I believe that this test will find utility in many countries around the world. Workshops are currently being planned to train people to use the test by various major public health organizations both internationally and in the United States. Calypte is supporting those efforts and believes that it will result in wider use of the tests. For some of these researchers, the Incidence Test will fe their first exposure to Calypte, and we anticipate that their experience with the innovation of the Incidence Test will fuel an interest in our other HIV assays as well."
Zurück
gelegenheit. :O).mal schaun, wie weit es franffurt runter drückt. hab nen schönen niedrigen kk eingegeben. 
